TORONTO, Jan. 22, 2020 /CNW/ - PharmaCielo
Ltd. ("PharmaCielo" or the "Company")
(TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of
Colombia's premier cultivator and
producer of medicinal-grade cannabis extracts, PharmaCielo Colombia
Holdings S.A.S., is pleased to announce that it has been included
in the newly created S&P/TSX Cannabis Index (XCAN). The XCAN is
composed of a select group of issuers traded on the TSX and TSX
Venture Exchanges, each of which has been vetted by the TSX Market
Intelligence Group.
About PharmaCielo
PharmaCielo Ltd. (TSXV: PCLO,
OTCQX: PCLOF) is a global company, headquartered in Canada, with a focus on ethical and
sustainable processing and supplying of all natural,
medicinal-grade cannabis oil extracts and related products to large
channel distributors. PharmaCielo's principal (and wholly owned)
subsidiary is GAP-certified PharmaCielo Colombia Holdings S.A.S.,
headquartered at its nursery and propagation centre located in
Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
SOURCE PharmaCielo Ltd.